KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Payables (2016 - 2026)

Pacira BioSciences has reported Payables over the past 17 years, most recently at $14.0 million for Q1 2026.

  • For Q1 2026, Payables fell 39.53% year-over-year to $14.0 million; the TTM value through Mar 2026 reached $14.0 million, down 39.53%, while the annual FY2025 figure was $15.2 million, 20.82% down from the prior year.
  • Payables for Q1 2026 was $14.0 million at Pacira BioSciences, down from $15.2 million in the prior quarter.
  • Over five years, Payables peaked at $30.1 million in Q2 2025 and troughed at $9.0 million in Q1 2024.
  • A 5-year average of $17.5 million and a median of $16.5 million in 2023 define the central range for Payables.
  • Biggest five-year swings in Payables: tumbled 47.96% in 2024 and later surged 157.98% in 2025.
  • Year by year, Payables stood at $15.2 million in 2022, then grew by 3.14% to $15.7 million in 2023, then increased by 21.88% to $19.1 million in 2024, then decreased by 20.82% to $15.2 million in 2025, then decreased by 7.51% to $14.0 million in 2026.
  • Business Quant data shows Payables for PCRX at $14.0 million in Q1 2026, $15.2 million in Q4 2025, and $17.7 million in Q3 2025.